Real‐World Effectiveness of Evolocumab in Reducing Major Adverse Cardiovascular Events: A Cohort Study
Key result
Evolocumab continuation is linked to a ~20% lower risk of MI, stroke, or revascularization versus discontinuation.
- RR 0.80
- 95% CI 0.73-0.86
- n=111,711
Why the study?
Does evolocumab continuation reduce the composite of myocardial infarction, stroke, or coronary revascularization in adults with atherosclerotic cardiovascular disease?
Key Points
- To assess the real-world effectiveness of evolocumab in reducing major adverse cardiovascular events among adults with atherosclerotic cardiovascular disease in routine clinical practice.
- Retrospective cohort study of US adults with atherosclerotic cardiovascular disease initiating evolocumab between 2017 and 2023 from the Komodo Healthcare Map.
- Patients were classified at day 75 as treated (continued evolocumab, n=87,102) or nontreated (discontinued before day 75, n=24,609) and followed for up to 4 years.
- Inverse probability of treatment and censoring weights were applied to adjust for confounding, with negative control outcomes utilized to evaluate residual bias.
- At 4 years, evolocumab-treated patients had a 20% lower risk of the primary composite outcome of myocardial infarction, stroke, or coronary revascularization compared with nontreated patients (RR, 0.80 [95% CI, 0.73–0.86]).
- Treated patients experienced a 29% lower risk of the secondary composite outcome of myocardial infarction, stroke, or cardiovascular disease death (RR, 0.71 [95% CI, 0.64–0.78]).
Study Design
Type
Cohort (n=111,711)
Structured PICO
Does evolocumab continuation reduce the composite of myocardial infarction, stroke, or coronary revascularization in adults with atherosclerotic cardiovascular disease?
P
Population
111,711 US adults with atherosclerotic cardiovascular disease who initiated evolocumab, followed for up to 4 years.
E
Exposure
Evolocumab continuation (remained on therapy at day 75 after initiation)
C
Comparator
Evolocumab discontinuation (discontinued therapy before day 75 after initiation)
O
Outcome
Composite of myocardial infarction, stroke, or coronary revascularization at 4 yearscomposite
Main Result
Relative Risk: 0.8 (95% CI 0.73–0.86)
In a real-world cohort of US adults with ASCVD, continuation of evolocumab was associated with a significant reduction in major adverse cardiovascular events at 4 years compared to early discontinuation.
Key expert perspectives
Captured external expert commentary on this paper, strongest first. Original sources are linked where available.
“I think my take-home message from these data is that reducing LDL cholesterol remains the cornerstone for reducing adverse cardiovascular events among patients with atherosclerotic cardiovascular disease. These real-world data now show what we had seen and learned from prior randomized trials and really holds true in the real-world setting and again demonstrates the effectiveness of evolocumab in reducing cardiovascular risk in patients with atherosclerotic cardiovascular disease.”
“It is compelling to see the benefits observed in the FOURIER trial reflected in a real-world patient population treated with Repatha.”
LBLeandro BoerUS Medical Therapeutic Area Head, Amgen
“Clinical trials have demonstrated Repatha's ability to significantly reduce the risk of major cardiovascular events in adults at high-risk. This analysis of real-world data in more than 110,000 patients with cardiovascular disease confirms those benefits in everyday care. Beyond underscoring the utility of Repatha, these results reinforce the urgency for healthcare providers to help patients achieve guideline-recommended LDL-C goals and lower their risk of life-altering events like heart attack or stroke.”
Implication
Associated MACE reduction supports evolocumab continuation in ASCVD; extends RCT evidence to real-world cohorts but should not yet change practice.
Abstract
BACKGROUND: Evolocumab reduces major adverse cardiovascular events in randomized trials, but evidence of its effectiveness in real-world clinical practice remains limited. METHODS: US adults with atherosclerotic cardiovascular disease who initiated evolocumab between 2017 and 2023 were identified from the Komodo Healthcare Map. At day 75 after initiation (index date), patients were classified as treated (remained on evolocumab) or nontreated (discontinued evolocumab before day 75). Patients were followed until the earliest of outcome occurrence, evolocumab discontinuation (treated group) or reinitiation (nontreated group), insurance disenrollment, end of database, or death. The primary outcome was a composite of myocardial infarction, stroke, or coronary revascularization; the secondary outcome was a composite of myocardial infarction, stroke, or cardiovascular disease death. Four-year cumulative incidence, risk ratios (RR), and 95% CIs were estimated, adjusting for confounders and informative censoring using inverse probability of treatment and censoring weights. Negative control outcomes were used to assess residual confounding before initiating comparative outcome analyses. RESULTS: After weighting, baseline characteristics were well balanced between treated (n=87 102) and nontreated (n=24 609) groups. At 4 years, treated patients had a 20% lower risk of the primary outcome (RR, 0.80 [95% CI, 0.73-0.86]) and a 29% lower risk of the secondary outcome (RR, 0.71 [95% CI, 0.64-0.78]) compared with nontreated patients. CONCLUSIONS: In a large, diverse, real-world population with atherosclerotic cardiovascular disease, evolocumab use was associated with significant reductions in major adverse cardiovascular events, supporting the effectiveness of guideline-recommended PCSK9 (proprotein convertase subtilisin/kexin type 9) inhibitor therapy in routine clinical practice.
Discussion
No takes yet. Share an insight, caveat, or question.
Cite This Study
Jin et al. (2026) conducted a cohort in Atherosclerotic cardiovascular disease (n=111,711). Evolocumab vs. Nontreated (discontinued evolocumab before day 75) was evaluated on Composite of myocardial infarction, stroke, or coronary revascularization (RR 0.80, 95% CI 0.73-0.86). Evolocumab continuation was associated with a 20% lower risk of myocardial infarction, stroke, or coronary revascularization compared with discontinuation (RR 0.80; 95% CI 0.73-0.86).